StockNews.com Initiates Coverage on Genocea Biosciences (NASDAQ:GNCA)
StockNews.com Initiates Coverage on Genocea Biosciences (NASDAQ:GNCA)
A hedge fund recently raised its stake in Genocea Biosciences stock. Commonwealth Equity Services LLC boosted its position in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) by 49.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 31,981 shares of the biotechnology company's stock after buying an additional 10,576 shares during the quarter. Commonwealth Equity Services LLC owned approximately 0.06% of Genocea Biosciences worth $37,000 as of its most recent filing with the Securities & Exchange Commission. 59.25% of the stock is owned by hedge funds and other institutional investors. Equities researchers at StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a research note issued to investors on Friday. The brokerage set a "sell" rating on the biotechnology company's stock.
斯托克新聞網的股票研究人員在週五發佈給投資者的一份研究報告中開始報道Genocea Biosciences(納斯達克：GNCA-GET評級)的股票。該經紀公司對這家生物技術公司的股票設定了“賣出”評級。
Several other equities analysts also recently issued reports on GNCA. Stifel Nicolaus downgraded shares of Genocea Biosciences from a "buy" rating to a "hold" rating in a research note on Friday, April 29th. HC Wainwright downgraded shares of Genocea Biosciences from a "buy" rating to a "neutral" rating in a research note on Friday, April 29th. Finally, Robert W. Baird lowered their target price on shares of Genocea Biosciences from $8.00 to $3.00 in a research note on Monday, April 11th.
其他幾位股票分析師最近也發佈了關於GNCA的報告。Stifel Nicolaus在4月29日星期五的一份研究報告中將Genocea Biosciences的股票評級從“買入”下調至“持有”。在4月29日星期五的一份研究報告中，HC Wainwright將Genocea Biosciences的股票評級從“買入”下調至“中性”。最後，羅伯特·W·貝爾德在4月11日星期一的一份研究報告中將Genocea Biosciences的目標股價從8.00美元下調至3.00美元。
Shares of NASDAQ:GNCA opened at $0.01 on Friday. The company has a market cap of $828,149.40, a price-to-earnings ratio of -0.02 and a beta of 2.26. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35. The firm has a 50 day simple moving average of $0.10 and a 200 day simple moving average of $0.69. Genocea Biosciences has a one year low of $0.01 and a one year high of $2.24.
納斯達克：GNCA的股票週五開盤報0.01美元。該公司市值為828,149.40美元，本益比為-0.02，貝塔係數為2.26。該公司的債務權益比為0.24，流動比率為1.35，速動比率為1.35。該公司的50日簡單移動均線切入位為0.10美元，200日簡單移動均線切入位為0.69美元。Genocea Biosciences的一年低點為0.01美元，一年高位為2.24美元。
A hedge fund recently raised its stake in Genocea Biosciences stock. Commonwealth Equity Services LLC boosted its position in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) by 49.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 31,981 shares of the biotechnology company's stock after buying an additional 10,576 shares during the quarter. Commonwealth Equity Services LLC owned approximately 0.06% of Genocea Biosciences worth $37,000 as of its most recent filing with the Securities & Exchange Commission. 59.25% of the stock is owned by hedge funds and other institutional investors.
一家對沖基金最近增持了Genocea Biosciences股票。據最近提交給美國證券交易委員會的檔案顯示，Federal Equity Services LLC在第四季度將其在Genocea Biosciences，Inc.(納斯達克代碼：GNCA-GET評級)的股票持倉量提高了49.4%。該基金持有這家生物技術公司31,981股股票，在本季度又購買了10,576股。截至最近向美國證券交易委員會提交的檔案，不列顛國協股權服務公司擁有Genocea Biosciences公司約0.06%的股份，價值3.7萬美元。59.25%的股票由對沖基金和其他機構投資者持有。
About Genocea Biosciences (Get Rating)
關於Genocea生物科學(獲取評級)
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Genocea Biosciences，Inc.是一家生物製藥公司，發現和開發新型癌症免疫療法。該公司使用其專有的發現平臺ATLAS，該平臺描述了每個患者對下一代腫瘤測序確定的每個目標或抗原的CD4+和CD8+T細胞免疫反應。
Further Reading
進一步閱讀
- Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
- Credo Technology Stock is Rebounding
- Investing In Preferred Stock vs. Common Stock
- Profiting From 52 Week Low Stocks
- Three Cheap Stocks The Insiders Are Buying
- Is Roblox A Good Play For The 2nd Half
- 免費獲取StockNews.com關於基因組生物科學的研究報告(GNCA)
- 信實科技股正在反彈
- 投資優先股與普通股
- 從52周低點的股票中獲利
- 內部人士正在買入的三隻廉價股票
- 羅伯克斯是下半場的好球員嗎？
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Genocea生物科學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Genocea Biosciences和相關公司的最新新聞和分析師評級的每日簡要摘要。
